PMID- 32459999
OWN - NLM
STAT- MEDLINE
DCOM- 20210611
LR  - 20210611
IS  - 2405-8025 (Electronic)
IS  - 2405-8025 (Linking)
VI  - 6
IP  - 6
DP  - 2020 Jun
TI  - Lipid in Renal Carcinoma: Queen Bee to Target?
PG  - 448-450
LID - S2405-8033(20)30078-9 [pii]
LID - 10.1016/j.trecan.2020.02.017 [doi]
AB  - Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer subtype, 
      characterized by a lipid storage phenotype. We found that carnitine 
      palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme of mitochondrial fatty 
      acid (FA) transport, is repressed by hypoxia-inducible factors (HIFs), reducing 
      FA oxidation (FAO). Altering lipid metabolism may be a new therapeutic avenue in 
      ccRCC.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Tan, Sze Kiat
AU  - Tan SK
AD  - Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, 
      University of Miami Miller School of Medicine, Miami, FL 33136, USA.
FAU - Welford, Scott M
AU  - Welford SM
AD  - Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, 
      University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic 
      address: scott.welford@med.miami.edu.
LA  - eng
PT  - Journal Article
DEP - 20200317
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Fatty Acids)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 1B37H0967P (endothelial PAS domain-containing protein 1)
RN  - EC 2.3.1.21 (CPT1A protein, human)
RN  - EC 2.3.1.21 (Carnitine O-Palmitoyltransferase)
RN  - EC 2.3.2.27 (Von Hippel-Lindau Tumor Suppressor Protein)
RN  - EC 6.3.2.- (VHL protein, human)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Basic Helix-Loop-Helix Transcription Factors/metabolism
MH  - Carcinoma, Renal Cell/*drug therapy/genetics/pathology
MH  - Carnitine O-Palmitoyltransferase/*antagonists & inhibitors/metabolism
MH  - Fatty Acids/metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - Kidney Neoplasms/*drug therapy/genetics/pathology
MH  - Lipid Droplets/metabolism
MH  - Lipid Metabolism/*drug effects/genetics
MH  - Mitochondria/drug effects/metabolism
MH  - Mutation
MH  - Oxidation-Reduction/drug effects
MH  - Peroxisomes/drug effects/metabolism
MH  - Proteolysis
MH  - Tumor Hypoxia/genetics
MH  - Von Hippel-Lindau Tumor Suppressor Protein/genetics/metabolism
OTO - NOTNLM
OT  - CPT1A
OT  - HIF
OT  - ccRCC
OT  - clear cell renal cell carcinoma
OT  - hypoxia
OT  - lipid metabolism
EDAT- 2020/05/28 06:00
MHDA- 2021/06/12 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/01/14 00:00 [received]
PHST- 2020/02/13 00:00 [revised]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/06/12 06:00 [medline]
AID - S2405-8033(20)30078-9 [pii]
AID - 10.1016/j.trecan.2020.02.017 [doi]
PST - ppublish
SO  - Trends Cancer. 2020 Jun;6(6):448-450. doi: 10.1016/j.trecan.2020.02.017. Epub 
      2020 Mar 17.